Managing Mergers With Sail Biomedicines' Guillaume Pfefer, Ph.D.

Business Of Biotech

We love to hear from our listeners. Send us a message.

While you might be aware that Sail Biomedicines was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger was executed, how the two companies are integrating their talent, IP, and resources, and what Sail Biomedicines CEO Dr. Guillaume Pfefer and team are currently doing to take the fruits of the company’s platform into the clinic. On this episode of the Business of Biotech, Dr. Pfefer takes us under the hood of Sail Biomedicines and its mission to marry evolution and AI to develop programmable medicines based on eRNA.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

章

1. Merger and Ambitions of Cell Biomedicine (00:00:00)

2. Global Perspective Shaping Leadership Style (00:17:14)

3. Immigrant Experience and Embracing Diversity (00:22:33)

4. Endless RNA and Programmable Medicine (00:27:01)

5. Partnerships and Speed in Fully-Programmed Medicine (00:40:28)

6. Biotech Podcast Business Introduction (00:50:04)